Investigational drug · Phase 3
THRV-1268
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Long QT Syndrome (LQTS) 2.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "THRV-1268"
First trial start
2026
Mar 7, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "THRV-1268", any sponsor or status.
Conditions studied
As listed on its trial records.
- Long QT Syndrome (LQTS) 2
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "THRV-1268" as an intervention, largest first.
- Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)Pivotal-lookingRecruiting
Thryv TherapeuticsIndustry
NCT07277582 · 84 participants (planned) · Start Mar 7, 2026 · Primary completion Jun 30, 2027
Drug: THRV-1268; THRV-1268 · For: Long QT Syndrome (LQTS) 2
Sites: Scottsdale, Arizona; San Francisco, California; Chicago, Illinois · 9 sites in all
Thryv TherapeuticsIndustry
NCT06507839 · 56 participants · Start May 15, 2024 · Primary completion Nov 1, 2024
Drug: THRV-1268 · For: Atrial Fibrillation
Sites: Montreal, Canada
Thryv TherapeuticsIndustry
NCT07186946 · 16 participants · Start Sep 15, 2025 · Primary completion Oct 20, 2025
Drug: THRV-1268; Placebo · For: Heart Failure
Sites: Overland Park, Kansas
Newest research
PubMed records naming it or its code names, newest first.
- Small-molecule inhibitors of SGK1: Structural basis, structure-activity relationships, and therapeutic perspectives.
Xie J, Wu W, Zhu G, et al. · Eur J Med Chem 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.